Stivarga

Active Ingredient(s): Regorafenib
FDA Approved: * September 27, 2012
Pharm Company: * BAYER HEALTHCARE PHARMS
Category: Cancer

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had two US approvals for advanced cancers. Contents 1 Approvals and indications... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
5 Discussions

Dosage List

Stivarga 40 mg Oral Tablet

NDC: 50419-171

Labeler:

Bayer Healthcare Pharmaceuticals Inc.

Popular Topics

Stivarga Adverse Effects

How did this drug, with its horrible side effects and minimal efficacy (6 weeks survival vs placebo), ever get approved?...

1 REPLY

Find stivarga in canada

My father is treated for a metastatic colorectal cancer since two years and now he is resistant to all therapeutic, his ...